Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ginkgo Bioworks Holdings, Inc. filings document an operating company focused on cell engineering, autonomous lab services, and biological R&D tools. Form 8-K reports record operating and financial results, material-event disclosures, governance matters, the completed Biosecurity divestiture, and the classification of that former business within discontinued operations.
Proxy and capital-markets filings cover board and shareholder voting matters, executive compensation, equity awards, and governance practices. The filing record also describes Ginkgo's Class A common stock listed on the NYSE under DNA, registration-statement activity, at-the-market offering arrangements, material agreements, and related capital-structure disclosures.
Ginkgo Bioworks insider plans another small Class A share sale. A holder has filed a notice to sell 2,200 shares of Class A common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $20,988.00. The filing lists 48,523,595 Class A shares outstanding.
The seller, identified as Austin Che, acquired these shares through restricted stock vesting in October 2022 as compensation from the issuer. Over the past three months, the same seller reported three separate NYSE sales of 2,200 Class A shares each, with gross proceeds of $23,716.00, $33,462.00, and $18,700.00. The notice also includes a representation that the seller is not aware of undisclosed material adverse information about the company’s current or prospective operations.
Ginkgo Bioworks Holdings, Inc.: Cascade Investment, L.L.C. and William H. Gates III reported beneficial ownership of 3,621,636 Class A shares, representing 7.5% of the class. William H. Gates III may be deemed to beneficially own these shares as the sole member of Cascade. The filing date of event is 09/30/2025.
The reported amount includes 299,052 earn-out shares that vest in equal tranches if the stock trades at specified price thresholds for 20 of 30 consecutive trading days before September 16, 2026, as outlined in the merger agreement. The holders report sole voting and dispositive power over 3,621,636 shares and no shared power. The percentage is based on 48,523,595 shares outstanding as of October 31, 2025. The certification states the securities are not held to change or influence control.
Form 144 filing: A stockholder filed notice to sell up to 2,200 shares of Class A common stock through Fidelity Brokerage Services, with an aggregate market value of $18,700, on or about 11/12/2025 on the NYSE.
The shares were acquired on 10/18/2022 via restricted stock vesting from the issuer as compensation. In the past three months, the filer (Austin Che) reported sales of 2,200 shares on 09/10/2025 for gross proceeds of $23,716 and 2,200 shares on 10/08/2025 for gross proceeds of $33,462. Shares outstanding were 48,523,595.
Ginkgo Bioworks (DNA) reported a smaller third quarter with a wider loss. Total revenue was $38.8 million, led by Cell Engineering at $29.4 million and Biosecurity at $9.5 million. The company recorded a net loss of $80.8 million and basic EPS of $1.45 loss, reflecting lower revenue and ongoing operating costs.
Liquidity shifted into marketable securities during 2025: cash and cash equivalents were $111.1 million and marketable securities were $350.8 million as of September 30, 2025. Net cash used in operating activities was $123.4 million for the nine months. Stockholders’ equity was $559.8 million.
Ginkgo launched a $100.0 million at‑the‑market program on September 4, 2025 and issued 975,300 Class A shares for $9.4 million in net proceeds. The restructuring begun in 2024 continued, with $10.7 million in year‑to‑date charges and expected workforce reduction costs of $28.0–$30.0 million. An amended Google Cloud agreement reset annual minimums and included a $21.4 million shortfall accrued and a one‑time $14.0 million payment in Q4 2025. As of October 31, 2025, shares outstanding were 48,523,595 Class A, 9,066,624 Class B, and 3,000,000 Class C.
Ginkgo Bioworks (DNA) furnished an 8-K announcing it issued a press release with its financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The filing, dated November 6, 2025, is an administrative disclosure under Item 2.02 (Results of Operations and Financial Condition) and includes the Inline XBRL cover page file as Exhibit 104.
Ginkgo Bioworks (DNA) filed a Form 4 for its CFO showing routine equity activity tied to RSU vesting. On 10/16/2025, restricted stock units were converted to Class A shares via code M in three tranches: 1,174 shares, 312 shares, and 1,061 shares.
On 10/17/2025, the CFO sold 1,312 shares at $13.649 per share under code S to cover tax withholding related to these vestings, as permitted by the company’s equity plans. Following the transactions, the CFO directly beneficially owned 6,738 Class A shares.
DNA filed a Form 144 notice for a proposed sale of 5,609 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 84,135. The approximate sale date listed is 10/21/2025.
The shares were acquired via restricted stock vesting as compensation on multiple dates in 2024, including 4,062 shares on 05/01/2024 and smaller vestings thereafter, totaling the amount to be sold. The filing lists 47,089,598 shares outstanding for the class. The section on recent activity shows a prior sale of 310 shares on 08/22/2025 for gross proceeds of 3,842.79.
DNA filed a Form 144 notice for a proposed sale of 1,312 shares of Class A common stock with an aggregate market value of $17,907.89, with an approximate sale date of 10/21/2025 on the NYSE through Fidelity Brokerage Services LLC.
The shares were acquired on 10/16/2025 via restricted stock vesting as compensation. In the past three months, Steve Coen sold 310 shares for gross proceeds of $3,842.79. Shares outstanding were 47,089,598; this is a baseline figure, not the amount being offered.
Ginkgo Bioworks Holdings, Inc. (DNA) filing a Form 144 notifies a proposed sale of 2,200 Class A shares held by the reporting person through Fidelity Brokerage Services. The shares were acquired on 10/18/2022 via restricted stock vesting as compensation. The filing lists an aggregate market value of $33,462.00 for the 2,200 shares and names the planned sale date as 10/08/2025 on the NYSE. The record also shows three prior Class A sales in the past three months totaling 6,600 shares with gross proceeds of $24,596.00, $31,020.00, and $23,716.00 on 07/09/2025, 08/06/2025, and 09/10/2025, respectively. The filer represents no undisclosed material adverse information and certifies the accuracy of the notice.
Ginkgo Bioworks Holdings, Inc. (DNA) reporting person Coen Steven P., identified as an officer (Chief Financial Officer), sold 5,609 shares of Class A common stock on 10/01/2025 at a reported price of $15 per share under a sales plan intended to comply with Rule 10b5-1. Following the reported disposition, the filing shows the reporting person beneficially owns 5,503 shares, held directly. The Form 4 was signed by an attorney-in-fact, Karen Tepichin, on 10/03/2025. The filing includes an explicit remark that the sale was made pursuant to a Rule 10b5-1 plan and identifies the reporting person as the company’s Chief Financial Officer.